Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Sep 28, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell

This study evaluated the effectiveness of short-course (2 cycles) ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) chemotherapy with interim PET scanning in previously untreated patients with early-stage (stage 1 – 2) Hodgkin’s lymphoma (HL). This study concluded that short-course ABVD was effective in the majority of patients who had negative PET scan results (no signs of cancer).

Some background

The majority of patients with early-stage HL can receive effective treatment with radiation therapy, with or without chemotherapy. However, radiation therapy has been associated with late complications, such as secondary cancers and heart disease.

Previous studies have shown that ABVD chemotherapy alone can achieve good outcomes for these patients without radiotherapy. PET scanning during (interim) and after chemotherapy may help predict treatment outcomes and plan further treatments. The outcomes of patients with early-stage HL after ABVD chemotherapy remain under investigation.

Methods & findings

This study involved 149 previously untreated patients with early-stage HL. Patients received 2 cycles of ABVD chemotherapy followed by PET scanning. Patients with negative PET scan results received 2 more cycles of ABVD. Patients with positive PET scan results received further treatments, including radiation. Patients were followed-up for an average of 3.8 years.

After ABVD chemotherapy, 91% of patients had negative PET scan results. 97% of the PET-negative and 85% of the PET-positive patients achieved a complete response (disappearance of all signs of cancer).

At follow-up, the 3-year progression-free survival (patients still alive 3 years later without disease progression; PFS) was 89%. PFS was significantly higher in the PET-negative group compared to the PET-positive group (91% vs. 66%). Positive PET scan results were associated with a 3.84-fold lower PFS.

The bottom line

This study concluded that short-course ABVD was effective in most patients with early-stage HL. This was true especially in patients who had negative PET scan results.

The fine print

This was a Phase 2 study. Further studies are needed to determine the role of short-course ABVD chemotherapy in the treatment of newly diagnosed patients with early-stage HL.

Published By :


Date :

Jul 26, 2018

Original Title :

CALBG 50604: risk-adapted treatment of non-bulky early stage Hodgkin lymphoma based on interim PET.

click here to get personalized updates